Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis

Autor: Yasar, N, Arici, S, Karatas, F, Geredeli, C, Sahin, S, Sakin, Abdullah, Atci, MM, Cihan, S, Sakin, A

Purpose: This study aimed to assess the effect of pretreat- ment albumin-bilirubin (ALBI) score on treatment outcomes in pancreatic cancer (PC) patients with liver metastasis at the time of diagnosis treated with chemotherapy (CT) in the first-line s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10157::7da559fbe087682f62e2a21c957566e5
https://avesis.yyu.edu.tr/publication/details/75fd85b4-d7fa-4fcf-8759-ff97c5a47bfb/oai

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.

Autor: Arikan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Atci MM; Department of Internal Medicine, Division of Medical Oncology, Professor Dr Cemil Tascioglu City Hospital, Istanbul 34384, Turkey., Ay S; Department of Internal Medicine, Division of Medical Oncology, Medeniyet University, School of Medicine, Istanbul 34722, Turkey., Ayhan M; Department of Internal Medicine, Division of Medical Oncology, Istanbul Kartal Lutfi Kirdar Education and Training Hospital, Istanbul 34865, Turkey., Demircan NC; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Telli TA; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Çelebi A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Yaşar A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Işik S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Celikel C; Department of Pathology, Marmara University School of Medicine, Istanbul 34899, Turkey., Balvan O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Bayoglu IV; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Kostek O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul 34899, Turkey., Dane F; Department of Internal Medicine, Division of Medical Oncology, Acıbadem University School of Medicine, Istanbul 34758, Turkey., Yumuk PF; Department of Internal Medicine, Division of Medical Oncology, Koc University School of Medicine, Istanbul 34010, Turkey.

Publikováno v: Oncology letters [Oncol Lett] 2023 Apr 05; Vol. 25 (5), pp. 208. Date of Electronic Publication: 2023 Apr 05 (Print Publication: 2023).

The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.

Autor: Atci MM; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey., Akagunduz B; Department of Medical Oncology, Erzincan Binali Yıldrıım University Medical School, Erzincan, Turkey., Demir M; Department of Medical Oncology, Erzurum Training and Research Hospital, Erzurum, Turkey., Arikan R; Department of Medical Oncology, Marmara University Medical School, Istanbul, Turkey., Ay S; Department of Medical Oncology, Istanbul Medeniyet University, Goztepe Education and Research Hospital, Istanbul, Turkey., Ozer M; Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, United States., Ayhan M; Department of Medical Oncology, Kartal Lutfi Kırdar Research Hospital, Istanbul, Turkey., Cil I; Department of Medical Oncology, University of Health Sciences, Umranıye training and Research hospital, Istanbul, Turkey., Demir N; Department of Medical Oncology, Eskisehir Osmangazi University Medical School, Eskişehir., Ozyurt N; Department of Medical Oncology, Gıresun Research Hospital, Gıresun, Turkey., Karakaya G; Department of Medical Oncology, Mardın, Research Hospital, Mardın, Turkey., Cevik GT; Department of Medical Oncology, Usak Research Hospital, Usak, Turkey., Onder AH; Department of Medical Oncology, University of Health Sciences, Antalya training and Research hospital, Antalya, Turkey., Selvi O; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey., Sakin A; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey.

Publikováno v: Journal of chemotherapy (Florence, Italy) [J Chemother] 2023 Feb; Vol. 35 (1), pp. 19-28. Date of Electronic Publication: 2022 Feb 17.

Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.

Autor: Goktas Aydin S; Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey., Cakan Demirel B; Medical Faculty, Department of Medical Oncology, Pamukkale University Hospital, Denizli, Turkey., Bilici A; Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey., Topcu A; Medical Faculty, Department of Medical Oncology, Bezmi Alem Vakıf University, Istanbul, Turkey., Aykan MB; Gülhane Education & Research Hospital, Department of Medical Oncology, Ankara, Turkey., Kahraman S; Department of Medical Oncology, Ankara Yildirim Beyazit University Hospital, Ankara, Turkey., Akbıyık I; Department of Medical Oncology, Ankara University Hospital Medical Faculty, Ankara, Turkey., Atci MM; Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey., Olmez OF; Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey., Yaren A; Medical Faculty, Department of Medical Oncology, Pamukkale University Hospital, Denizli, Turkey., Sendur MAN; Department of Medical Oncology, Ankara Yildirim Beyazit University Hospital, Ankara, Turkey., Geredeli C; Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey., Seker M; Medical Faculty, Department of Medical Oncology, Bezmi Alem Vakıf University, Istanbul, Turkey., Urun Y; Department of Medical Oncology, Ankara University Hospital Medical Faculty, Ankara, Turkey., Karadurmus N; Gülhane Education & Research Hospital, Department of Medical Oncology, Ankara, Turkey., Aydin A; Medical Faculty, Department of Internal Medicine, Istanbul Medipol University, Istanbul, Turkey.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2022 Oct; Vol. 38 (10), pp. 1751-1758. Date of Electronic Publication: 2022 Aug 16.

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

Autor: Özdemir Ö; Departments of Medical Oncology., Zengel B; General Surgery, Bozyaka Training and Research Hospital., Yildiz Y; Department Medical of Oncology, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir., Uluç BO; Department of Medical Oncology, Acibadem Hospital, Istanbul., Cabuk D; Department of Medical Oncology, Kocaeli University Faculty of Medicine Hospital, Kocaeli., Ozden E; Department of Medical Oncology, Kocaeli University Faculty of Medicine Hospital, Kocaeli., Salim DK; Department of Medical Oncology, Health Sciences University Antalya Training and Research Hospital, Antalya., Paydas S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Demir A; Department of Medical Oncology, Acibadem Hospital, Istanbul., Diker O; Department of Medical Oncology, Near East University Hospital, Lefkosa, Cyprus., Pilanci KN; Department of Medical Oncology, Memorial Bahcelievler Hospital., Sönmez ÖU; Department of Medical Oncology, Acibadem Hospital, Istanbul., Vatansever S; Department of Medical Oncology, Istanbul University Faculty of Medicine, Istanbul., Dogan I; Department of Medical Oncology, Istanbul University Faculty of Medicine, Istanbul., Gulmez A; Department of Medical Oncology, Inonu University Faculty of Medicine, Malatya., Cakar B; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir., Gursoy P; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir., Yildirim ME; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul., Ayhan M; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul., Karadurmus N; Department of Medical Oncology, Health Sciences University Gulhane Training and Research Hospital, Ankara., Aykan MB; Department of Medical Oncology, Health Sciences University Gulhane Training and Research Hospital, Ankara., Cevik GT; Department of Medical Oncology, Usak University Training and Research Hospital, Usak., Sakalar T; Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras., Hacibekiroglu I; Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya., Gülbagci BB; Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya., Dincer M; Department of Medical Oncology, Osmangazi University Faculty of Medicine Hospital, Eskisehir., Garbioglu DB; Department of Medical Oncology, Osmangazi University Faculty of Medicine Hospital, Eskisehir., Kemal Y; Department of Medical Oncology, Medical Park Hospital, Samsun., Nayir E; Department of Medical Oncology, Medical Park Hospital, Mersin., Taskaynatan H; Department of Medical Oncology, Private Ege City Hospital, Izmir., Yilmaz M; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul., Avci O; Department of Medical Oncology, Namik Kemal University Hospital, Tekirdag., Sari M; Department of Medical Oncology, Haydarpaşa Numune Training and Research Hospital., Coban E; Department of Medical Oncology, Haydarpaşa Numune Training and Research Hospital., Atci MM; Department of Medical Oncology, Prof. Dr. Cemil Tascioğlu City Hospital, Istanbul., Esen SA; Department of Medical Oncology, Ankara City Hospital, Ankara., Telli TA; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul., Karatas F; Department of Medical Oncology, Karabuk University Faculty of Medicine, Karabuk., Inal A; Department of Medical Oncology, Mersin City Training and Research Hospital, Mersin., Demir H; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar., Kalkan NO; Department of Medical Oncology, Van Yuzuncu Yil Faculty of Medicine, Van., Yilmaz C; Departments of Medical Oncology., Tasli F; Department of Pathology, Bozyaka Training and Research Hospital, Izmir, Turkey., Alacacioglu A; Department Medical of Oncology, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir.

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2022 Aug 01; Vol. 33 (7), pp. 663-670. Date of Electronic Publication: 2022 Jun 20.